PDF(Pubmed)
Abstract：
OBJECTIVE: To determine the effect of smoking on the response to anti-vascular endothelial growth factor (anti-VEGF) therapy treatment in patients with diabetic macular edema (DME).
METHODS: This is a retrospective case - control study that included 60 eyes with DME. Smoking habits were obtained from hospital records and patient recall. Patients were divided into two groups: the ever-smoker group and the never-smoker group. All patients received Intravitreal ranibizumab with three loading doses followed by PRN protocol and all were followed up for at least 1 year. Outcome measures were best-corrected visual acuity (BCVA), central retinal thickness (CRT) at the fovea, and number of visits.
RESULTS: Smoking was not associated with worse posttreatment visual acuity and was not found to influence the change in ocular coherence tomography measurement of central macular thickness and the change in BCVA (posttreatment minus pretreatment). There were no statistically significant differences in the duration of treatment or number of visits between two groups of patients the ever-smoker group and the never-smoker group (P > 0.05).
CONCLUSIONS: In this study, smoking status did not influence the treatment outcome of anti-VEGFs; however, smoking should be encouraged due to its well-known other systemic unwanted effects.
METHODS: This is a retrospective case - control study that included 60 eyes with DME. Smoking habits were obtained from hospital records and patient recall. Patients were divided into two groups: the ever-smoker group and the never-smoker group. All patients received Intravitreal ranibizumab with three loading doses followed by PRN protocol and all were followed up for at least 1 year. Outcome measures were best-corrected visual acuity (BCVA), central retinal thickness (CRT) at the fovea, and number of visits.
RESULTS: Smoking was not associated with worse posttreatment visual acuity and was not found to influence the change in ocular coherence tomography measurement of central macular thickness and the change in BCVA (posttreatment minus pretreatment). There were no statistically significant differences in the duration of treatment or number of visits between two groups of patients the ever-smoker group and the never-smoker group (P > 0.05).
CONCLUSIONS: In this study, smoking status did not influence the treatment outcome of anti-VEGFs; however, smoking should be encouraged due to its well-known other systemic unwanted effects.
摘要：
目的：探讨吸烟对糖尿病性黄斑水肿（DME）患者抗血管内皮生长因子（抗VEGF）治疗反应的影响。
方法：这是一项回顾性病例对照研究，包括60只眼DME。吸烟习惯来自医院记录和患者回忆。患者分为两组：吸烟者组和从不吸烟者组。所有患者均接受3种负荷剂量的玻璃体内雷珠单抗，随后接受PRN方案，所有患者均随访至少1年。结果指标是最佳矫正视力（BCVA），中央凹的中央视网膜厚度（CRT），和访问次数。
结果：吸烟与治疗后视力恶化无关，并且未发现吸烟会影响中央黄斑厚度的眼相干断层扫描测量值的变化和BCVA的变化（治疗后减去预处理）。两组患者的治疗时间和就诊次数比较,均无统计学差异(P>0.05)。
结论：在这项研究中，吸烟状况并不影响抗VEGF的治疗结果；然而，由于其众所周知的其他系统性有害影响，应鼓励吸烟。
方法：这是一项回顾性病例对照研究，包括60只眼DME。吸烟习惯来自医院记录和患者回忆。患者分为两组：吸烟者组和从不吸烟者组。所有患者均接受3种负荷剂量的玻璃体内雷珠单抗，随后接受PRN方案，所有患者均随访至少1年。结果指标是最佳矫正视力（BCVA），中央凹的中央视网膜厚度（CRT），和访问次数。
结果：吸烟与治疗后视力恶化无关，并且未发现吸烟会影响中央黄斑厚度的眼相干断层扫描测量值的变化和BCVA的变化（治疗后减去预处理）。两组患者的治疗时间和就诊次数比较,均无统计学差异(P>0.05)。
结论：在这项研究中，吸烟状况并不影响抗VEGF的治疗结果；然而，由于其众所周知的其他系统性有害影响，应鼓励吸烟。
